1. The effect of previous treatment with bisphosphonate and renal impairment on the response to denosumab in osteoporosis: a ‘real-life’ study
- Author
-
Geeta Hampson, Amelia E. B. Moore, I Flogaitis, and T R Fraser
- Subjects
Male ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Osteoporosis ,030232 urology & nephrology ,Urology ,030209 endocrinology & metabolism ,Group B ,03 medical and health sciences ,Absorptiometry, Photon ,0302 clinical medicine ,Endocrinology ,Bone Density ,Chronic kidney disease ,medicine ,Bisphosphonate ,Humans ,Renal Insufficiency, Chronic ,Aged ,Retrospective Studies ,Femoral neck ,Aged, 80 and over ,Bone mineral ,Hip ,Bone Density Conservation Agents ,Diphosphonates ,business.industry ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Spine ,Treatment Outcome ,Denosumab ,medicine.anatomical_structure ,Original Article ,Female ,Bone Remodeling ,business ,Kidney disease ,medicine.drug - Abstract
Purpose To investigate changes in bone mineral density (BMD) following denosumab after previous bisphosphonate therapy and the impact of chronic kidney disease (CKD) on response. Methods A retrospective study of 134 patients (11 M, 123 F) aged [mean (SD)] 72 [11] years on denosumab was undertaken. Ninety-five patients had previously been on oral and 28 on iv bisphosphonate. Lumbar spine (LS), total hip (TH) and femoral neck (FN) BMD were measured before treatment and at 2.7 [1.2] years. GFR was Results BMD improved following denosumab [mean (SEM) % change LS: 6.0 (0.62) p p p = 0.045]. Changes at the TH and FN were lower in patients with GFR 35 ml/min (Group A) [% change TH; Group A: 2.9 (0.72), Group B: − 0.84 (1.28), p = 0.015, FN; Group A: 2.76 (0.86), Group B: − 1.47 (1.53), p = 0.025]. % change in BMD at the FN and PTH were negatively associated (r = − 0.25, p = 0.013). BMD changes were not different at 12–18 months between patients on denosumab compared to zoledronate [% change at LS: denosumab: 3.97% (0.85), zoledronate: 2.6% (0.5), p = 0.19 TH: denosumab: 0.97% (0.58), zoledronate: 0.92% (0.6), p = 0.95). Conclusion Denosumab increases BMD following previous bisphosphonate treatment and is comparable to zoledronate. Lower response seen at the hip in CKD is related to PTH concentrations.
- Published
- 2019
- Full Text
- View/download PDF